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How to Modify the Substrate?Hans Kottkamp, MD, Roderich Bender, MD, Jan Berg, MDABSTRACTFro
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MaA frequent need for re-ablations and limited overall success rates are still major limitations of catheter ablation proce-
dures for the treatment of atrial ﬁbrillation (AF). These limitations include not only the durability of the pulmonary vein
isolation (PVI) lines, but also the pathophysiological understanding of the arrhythmia’s substrate. Long-term single
procedure success rates in non-paroxysmal AF are disappointingly low for current stepwise ablation approaches adding
the placement of linear lines and electrogram-based ablation after circumferential PVI isolation. In the future, substrate
modiﬁcation in AF ablation should move toward individualized patient-tailored ablation procedures. Magnetic resonance
imaging could play a major role for noninvasively describing the localization and extent of ﬁbrotic areas. Speciﬁc new
strategies that could be used include precise localization and ablation of rotors that maintain the arrhythmia using
multielectrode mapping during AF and box isolation of ﬁbrotic areas guided by electroanatomic voltage mapping during
sinus rhythm. (J Am Coll Cardiol 2015;65:196–206) © 2015 by the American College of Cardiology Foundation.P ercutaneous catheter ablation is widely usedas an interventional tool for rhythm controlin patients with atrial ﬁbrillation (AF) (1).
Circumferential pulmonary vein isolation (PVI), with
conﬁrmation of the entrance block, anchors this
procedure. However, this intervention produces a
frequent need for re-ablations and has limited overall
success rates. This is caused by limitations not only in
the durability of PVI lines, but also in our current un-
derstanding of the pathophysiology, especially of the
arrhythmia’s substrate.
A better understanding of the human atrial sub-
strate that maintains AF has led to the concept of
pre-existing speciﬁc ﬁbrotic atrial cardiomyopathy
(FACM), in which AF manifests from an individually
localized substrate (2,3). This may help explain why
circumferential PVI is effective in many, but not all,
patients with paroxysmal AF, and is also effective in
some patients with long-standing, persistent AF. In
addition, the extent and localization of an individual
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FIGURE 1 Light Microscopy of Crista Terminalis Specimen
A B
Lightmicroscopy of a crista terminalis specimen in a patient in (A) sinus rhythmandwithout a
history of atrialﬁbrillation (AF) showing no signiﬁcantﬁbrosis, and (B)persistent AF showing
a high level of ﬁbrosis. Courtesy of Pyotr Platonov, MD, and Lubov Mitrofanova, MD.
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
BIFA = box isolation of
ﬁbrotic areas
CFAE = complex fragmented
atrial electrogram
CT = computed tomography
DE-MRI = delayed
enhancement magnetic
resonance imaging
EAVM = electroanatomic
voltage mapping
FACM = ﬁbrotic atrial
cardiomyopathy
FIRM = focal impulse and
rotor mapping
LA = left atrial
PV = pulmonary vein
PVI = pulmonary vein isolation
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197time, all of which were characterized by progressive
ﬁbrosis and/or scarring of the atrial myocardium (5).
Fibrotic atrial structural remodeling has been
consistently described in AF patients in histological
and autopsy studies (6–8) (Figure 1). The presence of
(micro)ﬁbrosis leading to changes in cellular coupling
results in spatial “nonuniform anisotropic” impulse
propagation, which is a potential cause of atrial acti-
vation abnormalities underlying the initiation and
perpetuation of re-entrant arrhythmias like AF (9,10).
Recent clinical research has highlighted the presence
of atrial tissue ﬁbrosis using delayed-enhancement
magnetic resonance imaging (DE-MRI) and electro-
anatomic voltage mapping (EAVM) (11–14). Impor-
tantly, ﬁbrotic atrial changes vary in localization and
extent, and are principally bi-atrial ﬁndings. A higher
mean value of ﬁbrosis was detected in patients with
persistent AF versus paroxysmal AF; however, vari-
ability in the extent of ﬁbrosis among patients with
AF is very high (7). In addition, patients with so-
called “lone” AF may exhibit a substantial ﬁbrotic
substrate before and/or at the clinical advent of AF,
whereas other patients with a decades-long history of
AF do not develop a signiﬁcant ﬁbrotic substrate (3).
The most frequent manifestation combination of
bi-atrial FACM was described as bradycardia/tachy-
cardia syndrome with sick sinus node plus parox-
ysmal AF (2) (Figure 2). Importantly, the extent of the
ﬁbrotic atrial substrate is variable and has been clas-
siﬁed as FACM 0 to 3 (2,3) (Figure 3), which corre-
sponds to the DE-MRI study Utah classiﬁcation of 1 to
4 (12). Furthermore, the regional distribution of
patchy ﬁbrotic atrial areas varies signiﬁcantly from
patient to patient (Figures 4 and 5).
In other patients, the ﬁbrotic atrial substrate lead-
ing to increased AF susceptibility may result from se-
vere underlying structural heart disease (e.g., mitral
stenosis or hypertrophic obstructive cardiomyopa-
thy). An EAVM study in patients with rheumatic mitral
stenosis who underwent commissurotomy and who
did not have a history of AF described a signiﬁcantly
reduced bi-atrial voltage (15). Conversely, in an EAVM
series of patients with systemic hypertension plus left
ventricular hypertrophy, but no history of AF, the
mean right atrial voltage was identical in the hyper-
tension and control groups (16). In general, the impact
of “classic comorbidities” among patients undergoing
catheter ablation of AF seems to be overestimated, as
is the role of age on the ﬁbrotic substrate (3). In an MRI
study that compared left atrial (LA) structural changes
in patients with lone AF versus those with classic
comorbidities, the substrate was independent of
comorbidities (17). This corresponds well with a recent
autopsy study in which negligibly low amounts ofﬁbrosis were found in older patients with a
high CHA2DS2-VASc score (4.3), but who did
not have a history of AF; patient age was not
correlated with an increase in the extent of
atrial ﬁbrosis (8).
In addition to “substratemakers” like FACM
or mitral stenosis, “modulators” inﬂuence the
susceptibility of AF occurrence (e.g., obesity
and/or cardiometabolic syndrome, infections
and/or inﬂammation, surgery, and cancer).
Weight reduction with intensive risk factor
management substantially changed these
modulators in 1 study, and reduced AF symp-
tom burden and severity. Changing these
modulators was also beneﬁcial for cardiac
remodeling (18). With respect to surgery,
pre-operatively elevated serum markers of
collagen synthesis were associated with post-
surgical AF in patients without a history of
AF (19). Importantly, pre-existing LA ﬁbrosis
was signiﬁcantly higher in patients who developed
post-surgical AF compared with those who stayed in
sinus rhythm (19), which indicates toward the modu-
lating effects of cardiac surgery on previously sub-
clinical LA ﬁbrosis and/or FACM.
ATRIAL SUBSTRATE
MODIFICATION STRATEGIES
CIRCUMFERENTIAL PV ISOLATION. Within the evo-
lution of AF catheter ablation, circumferential PVI
FIGURE 2 Bi-Atrial Voltage Mapping
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These 3 patients had atrial ﬁbrillation (AF) and different right and/or left atrial low-voltage distribution. The patients had (A) normal voltages
in the anatomic region of the sinus node (SN) area and clinically normal sinus rhythm, (B) moderately reduced voltages in the SN area and
clinically mild sinus bradycardia, and (C) signiﬁcantly reduced voltages (0.22 mV) in the SN area and clinically severe sinus bradycardia. The
projections were anterior (AP), posterior (PA), and right lateral (RL). Color coding: red for voltages <0.5 mV and purple for voltages >1.5 mV.
CS ¼ coronary sinus; LPV ¼ left pulmonary veins; RPV ¼ right pulmonary veins.
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198extends the ablation sites to more proximal areas
away from focal ablation sites within the veins and
from distal sites of segmental PV disconnection (1).
Such proximal PVI isolates triggers within the PVs and
within the funnel-shaped left atrium–PV transition
area, and also affects the substrate necessary for
maintaining the arrhythmia. This may reﬂect a sub-
stantial atrial mass reduction, but it may also be
related to the speciﬁc nonuniform anisotropic
arrangement of the longitudinally- and spirally-
oriented atrial myocardial muscle sleeves fanning
out into the PVs. These muscle sleeves facilitate
re-entry, ﬁbrillatory wavelets, or rotors, and move
into the anatomical barriers of the PV ostia, thus
facilitating re-entry around these ostia (Central
Illustration). In a randomized clinical study, largeisolation areas were signiﬁcantly more effective
compared with small isolation areas around the PVs
(20). In some cases, the isolated PV areas could even
sustain AF themselves (Figure 6). Clearly, many pa-
tients with AF recurrences after PVI have PV re-
connection at the time of re-ablation (21). However,
the substrate modiﬁcation aspect of circumferential
PVI is supported by the observation that a substantial
portion of patients had no further AF episodes after
(acute) PVI despite re-connected PVs found at a
repeat study during follow-up (22).
LINEAR LINES. Linear line placement has been
investigated since the very ﬁrst days of AF catheter
ablation procedures 20 years ago. Forming contig-
uous lesion lines within the left atrium, which is
aimed at complete conduction block, was quickly
FIGURE 3 Voltage Mapping Showing Variable Severity of LA Fibrosis
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Variation of left atrial (LA) ﬁbrosis severity is seen in 4 patients with AF who have no signiﬁcant underlying cardiovascular disease. (A) Despite
a history of paroxysmal AF >10 years, the left atrium showed normal voltages. (B) In the anterior and posterior wall, patchy segments with
slightly reduced voltages were identiﬁed. (C) In the posterior wall, a conﬂuent area of substantially reduced voltage was identiﬁed. (D)
Substantial and diffuse reduced voltages are seen in the left atrium (the “strawberry”) despite a short history of AF. FACM ¼ ﬁbrotic atrial
cardiomyopathy; other abbreviations as in Figures 1 and 2.
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199found to be technically challenging (23). However,
surgically applied linear lesion line concepts
conﬁrmed the potential value of the placement of
strategic linear lines connecting the PVs, including
the 2 most frequently applied LA lines in AF percu-
taneous catheter ablation, the “roof line” and the
“mitral isthmus line,” even without PVI (24). Both of
these show an additive effect compared with PVI
alone, even in patients with paroxysmal AF (25,26).
One of the issues related to long linear line place-
ment remains the difﬁculty in achieving durable
complete conduction block across the lines; incom-
plete block due to gap development may not only
result in recurrence of AF, but may also lead to sus-
tained episodes of gap-related LA ﬂutter (27). Such a
proarrhythmic effect of a noncomplete line may lead
to secondary arrhythmias. One further limitation—
and, strategy wise, an even more important one—is
that placement of these empirical and purely
anatomically deﬁned lines does not address individ-
ual localization of the ﬁbrotic substrate.
ABLATION BASED ON ELECTROGRAM CHARACTERISTICS
DURING AF MAPPING. Clinical mapping studies have
shown that the recording of complex fractionated
atrial electrograms (CFAEs) during AF are correlatedwith slowed conduction and pivot points of wavelets
(28). These ﬁndings were then tested as target sites
for catheter ablation (29). These CFAEs, which were
recorded during AF, found to be bi-atrial phenomena,
and had a propensity for localization at the interatrial
septum, the PVs, the LA roof, the left posteroseptal
mitral annulus, and the coronary sinus ostium (29).
The deﬁnition of the CFAEs included fractionated
electrograms with $2 deﬂections, continuous de-
ﬂections of a prolonged activation complex over a
10-s recording period, and electrograms with a short
cycle length (#120 ms) averaged over a 10-s recording
period (29). Procedural endpoints included elimi-
nating CFAE sites, converting AF to sinus rhythm in
patients with paroxysmal and persistent AF, and
noninducibility of AF in patients with paroxysmal AF.
In a prospective, randomized multicenter study in
patients with a high burden of paroxysmal or persis-
tent AF, combining PVI and CFAE ablation resulted in
a signiﬁcantly higher freedom from AF compared
with either technique alone (30).
The potential limitations of CFAE mapping include
the unclear speciﬁcity of these different types of
electrograms, variable deﬁnition, temporal and
spatial resolution of CFAE site mapping, an extensive
FIGURE 4 Voltage Mapping Showing Variable Localization of LA Fibrosis
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(A) The low-voltage area was identiﬁed in the mid-posterior left atrium (LA). (B) A big low-voltage area was found in the anteroseptal area of
the LA. (C) Mildly reduced voltages were identiﬁed in the anteroseptal region and at the LA roof. (D) A big low-voltage area was found at the
inferoposterior portion of the left atrium. Abbreviations as in Figures 2 and 3.
Kottkamp et al. J A C C V O L . 6 5 , N O . 2 , 2 0 1 5
Substrate Modiﬁcation in AF Ablation J A N U A R Y 2 0 , 2 0 1 5 : 1 9 6 – 2 0 6
200amount of ablation, and the potential proarrhythmic
effect of multiple single-point ablations.
COMBINATION OF PVI, CFAE ABLATION, AND LINEAR
ABLATION. In clinical practice, different combinations
of these strategies are often applied in AF ablation
procedures. For example, a stepwise approach, inclu-
ding a combination of PVI followed by electrogram-
based ablation and linear lines, has been suggested for
patients with persistent and long-standing persistent
AF (31). However, success rates with a single procedure
remain very limited, even when applying stepwise
ablation to these different targets (31,32). The fre-
quent necessity for multiple ablation procedures has
done little to enhance long-term success rates in pa-
tients with persistent and long-standing persistent AF;
however, this approach has led to additive overall
procedure and/or ﬂuoroscopy times, additive compli-
cations per patient, and more ablated tissue, high-
lighting the need for new ablation strategies.
NOVEL ABLATION STRATEGIES
VOLTAGE MAP-GUIDED SUBSTRATE MODIFICATION:
BOX ISOLATION OF FIBROTIC AREAS. The regional
localization and the extent of the ﬁbrotic LA substrate
can be visualized during the intervention in sinusrhythm applying EAVM; this allows the use of a new
patient-tailored ablation strategy, box isolation of
ﬁbrotic areas (BIFAs), for the circumferential isolation
of the signiﬁcantly affected ﬁbrotic areas (e.g., <0.5
mV). We originally tested this strategy in patients
with paroxysmal AF who had recurrence of AF
despite durable PVI. EAVM identiﬁed 2 substantial
ﬁbrotic areas in the patient shown in Figure 7. The
anteroseptal ﬁbrotic area was circumferentially iso-
lated with a connection to the right PVI line, the
posterosuperior ﬁbrotic area was isolated using a roof
line plus a posterior line, and then both lines were
connected to the previous circumferential PVI lines.
After observing good clinical response, we ex-
tended this strategy to patients with persistent or
long-standing persistent AF. In these patients, we
isolated low-voltage areas even in the initial ablation
procedure. The PVs were isolated as the initial step.
After spontaneous or electrical cardioversion, a vol-
tage map was recorded during sinus rhythm; the
low-voltage areas were identiﬁed and subsequently
isolated according to individual localization and
extent. These BIFA ablation lines should, in general,
be connected to the initial PVI lines to prevent the
production of small channels and their potential
proarrhythmic effects.
FIGURE 5 Quantiﬁcation and Localization of LA Structural Remodeling With DE-MRI
A
B
Delayed-enhancement magnetic resonance imaging (DE-MRI) was performed in 2 patients
with substantial LA ﬁbrosis (“Utah classiﬁcation 3”), but who had different localization of
the substrate. (A) The patient showed substantial ﬁbrosis at the anterior wall and to a
lesser extent in the inferior wall. (B) The patient showed large areas of ﬁbrosis at the
posterior wall and to a much lesser extent at the anterior wall. Color coding: green for
enhancement and blue for normal tissue. Courtesy of Nassir Marrouche, MD. Abbreviations
as in Figures 2 and 3.
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201Circumferential PVI is the only initial ablation
strategy used by our group in patients with persistent
and long-standing persistent AF, but who are without
substantial low-voltage areas, and it was shown to be
successful in preventing further AF episodes. In the
relatively conservative “Hamburg sequential ablation
strategy” for patients with long-standing persistent
AF, 43% of patients remained in sinus rhythm after
circumferential PVI was used as the sole ablative
strategy (33). With additional CFAE ablation, left
linear lesions, and superior caval vein isolation, the
overall short-term success rate was reported to be
68%. During a 5-year follow-up, single and multiple
ablation procedural successes were 20% and 45%,
respectively. Importantly, one-half of the successes
were still achieved in patients who underwent
circumferential PVI alone (34).
In contrast, an individualized substrate modiﬁca-
tion using BIFAs may be added to circumferential PVI
in patients with paroxysmal AF, but who also have
very substantial regional LA ﬁbrosis detected in the
ﬁrst ablation session (Figure 8). Finally, in patients
with massive ﬁbrosis (the “strawberry” in Figure 3D),
failure of the initial ablation is likely regardless of the
applied ablation concept, and further ablation pro-
cedures should be discouraged and avoided.
Some years ago, posterior box isolation at the level
of the PVs was introduced (35). After placing lines at
the anterior aspect of the ipsilateral PVs, lines at the
LA roof and posterior left atrium were added to
completely isolate that area. Because of the variable
extent and localization of the ﬁbrotic areas, this
anatomically deﬁned substrate modiﬁcation did not
address the substrate’s individuality. For example,
such a posterior box isolation would have isolated
the posterior ﬁbrotic area of one patient (Figure 4A);
however, this procedure would have isolated a
completely normal posterior wall in another patient
(Figure 4C). This and other examples highlight the
substantial limitations of purely anatomically deﬁned
linear line placement in contrast to the individualized
BIFA substrate modiﬁcation.
THE ROLE OF MRI FOR SUBSTRATE DESCRIPTION
AND MODIFICATION. Recently, DE-MRI was intro-
duced for detecting, quantifying, and localizing atrial
ﬁbrosis, including the 4 Utah stages of structural
changes (11,12,17). In contrast to invasive EAVM, DE-
MRI seems to be an attractive noninvasive, repeat-
able diagnostic tool. The tissue characterization of
the LA wall on DE-MRI was correlated with EAVM (11)
and with the histology from surgical biopsy speci-
mens (12). Currently, this modality requires extensive
MRI experience, and its reproducibility is still under
investigation in other groups. Normalization ofDE-MRI by mean blood pool intensity is currently
being tested to overcome the necessity of operator
judgment to deﬁne the level of enhancement as-
signed to ﬁbrosis (36,37).
Identiﬁcation and acute targeting of gaps in atrial
ablation lesions sets have also been investigated us-
ing a real-time MRI system (38). In a swine model,
ablation lines with an intentional gap were created,
and the gap area was identiﬁed and ablated using
real-time MRI catheter navigation and visualization
(38). However, DE-MRI recently demonstrated insuf-
ﬁcient accuracy to reliably identify ablation lesions or
to determine lesion distribution (39). The quantiﬁca-
tion and localization of atrial ﬁbrosis might be used to
guide individually tailored substrate elimination
compared with EAVM-guided substrate modiﬁcation.
Finally, tissue visualization before, during, and
directly after radiofrequency catheter ablation is the
target for introducing real-time MRI into the clinical
electrophysiological laboratory.
CENTRAL ILLUSTRATION Regional Substrate Localization and
Individualized Ablation
(A) Regionally located ﬁbrotic substrate, including the rotors and/or re-entry that
maintain atrial ﬁbrillation. (B) Left-sided circumferential pulmonary vein isolation (PVI)
coincidentally eliminated 1 ﬁbrotic area, including a rotor. In addition, a box isolation of
the posterior–inferior ﬁbrotic area, including a rotor, was added and attached to the
right-sided PVI line. In contrast, a purely anatomically deﬁned roof line and mitral
isthmus line would not have interfered with the individual substrate location. In addi-
tion, a ﬁbrotic area was located in the sinus node region, which led to sinus bradycardia.
IVC ¼ inferior vena cava; LIPV ¼ left inferior pulmonary vein; LSPV ¼ left superior
pulmonary vein; RIPV ¼ right inferior pulmonary vein; RSPV ¼ right superior
pulmonary vein; SN ¼ sinus node; SVC ¼ superior vena cava.
FIGURE 6 Electrograms and 3-Dimensional Mapping
I
Sinus rhythm in the atria
Atrial fibrillation in RPV
Atrial fibrillation in LPV
II
V1
V6
LPV 1/2
Abl. RPV
LPV 3/4
LPV 5/6
LPV 7/8
LPV 9/10
CS 1/2
CS 3/4
RVA
Three-dimensional (3D) mapping and electrograms show AF can be maintained within the
isolated LPV and isolated RPV, but with the remaining left and right atria in sinus rhythm.
Surface electrocardiogram leads I, II, V1, and V6 plus intracardiac electrograms are given.
Abl ¼ ablation catheter; CS ¼ coronary sinus; RVA ¼ right ventricular apex; other
abbreviations as in Figure 2.
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202ROTOR MAPPING. Narayan et al. tested the hypoth-
esis that human AF is sustained by localized “sour-
ces” whose speciﬁc elimination might improve
outcome after ablation (Figure 9) (40). With this
strategy, which is called focal impulse and rotor
modulation (FIRM), a 64-pole basket catheter is
advanced into the left and right atria, and a compu-
tational approach maps the AF. In an extended
follow-up study, patients who underwent FIRM-
guided ablation maintained higher freedom from AF
versus those who underwent conventional ablation
(41). Overall, FIRM mapping revealed AF rotors or
focal sources in 98% of the patients, for 1.9  1.1
concurrent sources per patient, 67% of which were in
the left atrium and 33% in the right atrium (41).
Importantly, AF sources were analyzed to be coinci-
dentally ablated in 45% of conventional cases (e.g., at
the LA roof or near the PVs) (42) (Central Illustration).
These data might help explain why wide area PVI
is more effective than more distal PVI, and especially,
why patients might remain free of AF recurrences
despite PV re-connection. The encouraging results
obtained by elimination of patient-speciﬁc rotors
were recently conﬁrmed in a multicenter study (43).
This promising and novel technique is currently
limited by the relatively low number of 64 basket
electrodes and the nonuniform distribution of elec-
trodes with stable contact to the atrial wall. The
mapping data require propriety computational soft-
ware, and the results have yet to be reproduced by
others.
NONINVASIVE MAPPING OF AF. Data from simulta-
neous bi-atrial epicardial activation sequences during
AF using noninvasive electrocardiographic imaging
were published a few years ago (44). In that study,
256 electrodes were applied to the patient’s torso and
connected to a mapping system; patients then un-
derwent computed tomography (CT) imaging. AF
complexity increased with a longer clinical history of
AF, but the complexity of nonparoxysmal AF varied
widely. Recently, high-resolution images of the bi-
atrial geometry were described using an array of 252
body surface electrodes and thoracic CT (45). A spe-
ciﬁc signal-analysis process combined ﬁltering,
wavelet transformation, and phase mapping using
surface unipolar electrograms acquired during AF.
Using this technology, PV discharges, meandering
rotors, and their mutual interplay were detected, as
well as drifting rotors that were not stationary for
more than 2 rotations. Thus, noninvasive AF mapping
may identify active sources like (stable or unstable)
rotors and may help identify a patient-speciﬁc abla-
tion strategy.
FIGURE 7 Substrate Modiﬁcation and Conﬁrmation of Box Isolations
I
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V1
V6
Abl.
Box 1/2
Box 3/4
Box 5/6
Box 7/8
Box 9/10
CS 1/2
CS 3/4
RVA
Anterior Box Isolation Posterior Box Isolation
A B
C
A 61-year-old patient with “lone” AF presented with recurrent AF 1-year post-PVI. Mapping during the re-do procedure showed durable isolation of all PVs but sub-
stantial areas of low voltage at the anteroseptal (A) and posterior (B) left atrium. Anterior and posterior box isolation were performed (C)with connection to the previous
PVI lines; the box isolations were also conﬁrmed with a circular mapping catheter. Abbreviations as in Figure 1.
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203LIMITATIONS OF TECHNIQUES AND TECHNOLOGIES
FOR SUBSTRATE MODIFICATION. Durability of the
isolating lesions and/or lesion lines clearly remains an
issue, and the “true” success rate of pure circumfer-
ential PVI for paroxysmal and persistent AF is un-
known. The same issue of durability of ablation
points and/or lines holds true for BIFA lines for sub-
strate modiﬁcation guided by EAVM. Recent tech-
nology improvements of point-by-point catheter
approaches (e.g., contact force-sensing catheters) can
further pave the way. However, achieving the pro-
posed strategies for BIFA substrate modiﬁcation
described herein will require extensive operator
manual skills and experience. Therefore, new cath-
eter and/or array technologies for simultaneous
multielectrode contact mapping plus ablation may be
helpful, and are currently under investigation (46).
Methods to describe the ﬁbrotic substrate are also
being evaluated, but these methods face several limi-
tations. Voltage maps using point-by-point mappingnot only take time, but the measured voltage also de-
pends on the rhythm (sinus rhythm vs. extrasystole or
AF), the electrode contact with tissue, the atrial
myocardium thickness, and other variables. There-
fore, clear limits or deﬁnitions for a normal voltage
(e.g.,>1.5 mV,>2.0 mV) and a highly abnormal voltage
(e.g., <0.5 mV) are nonexistent. Also, there is no clear
voltage mapping limit for seemingly “complete scar”
because electrograms of <0.1 mV may have small de-
ﬂections that indicate few surviving atrial myocardial
ﬁbers. Moreover, substantial voltages can be recorded
in often patchy ﬁbrotic areas due to far-ﬁeld recording
with current 3.5-mm tip electrodes; however, the
overall spatial mapping resolution needed is unclear.
Limitations at this early stage of rotor mapping also
exist. The reproducibility of individual patient maps
over time, the duration of AF mapping required to
capture all potential sources, the role of epi-
endocardial dissociation, and necessary spatial map-
ping resolution are all under investigation.
FIGURE 8 Individually-tailored Ablation With Voltage Mapping
A C
DB
Two examples of patients undergoing AF ablation with voltage mapping and individually tailored ablation according to the substrate rather than the “phenotype”
(persistent vs. paroxysmal AF). (A) A patient with persistent AF showed completely normal voltages in most areas of the left atrium and only mildly reduced voltages
in the anteroseptal region. (B) Accordingly, solely circumferential PVI was performed. (C) A patient with paroxysmal AF showed substantial areas of very low voltage in
the anteroseptal and posteroinferior left atrium. (D) Additional substrate modiﬁcation was performed with speciﬁcally targeted box isolations. Abbreviations as in
Figures 1, 2, and 7.
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204Evidence is increasing with regard to the devel-
opment and progression of an atrial substrate inde-
pendent of AF, whether due to a primary FACM, some
other substrate makers and/or modulators, or some
combination of both. This may explain AF recurrence
following a period of stable sinus rhythm after abla-
tion with durable PVI. Such progression is seen with
other substrate-based arrhythmias (e.g., ventricular
tachycardia in ischemic or nonischemic ventricular
cardiomyopathy), in which remodeling of the sub-
strate after an initially successful ablation may lead to
new tachycardias. Furthermore, although many pa-
tients with AF present with individually localized
and/or patchy ﬁbrotic areas that ablation may spe-
ciﬁcally target, other patients present with diffuse,
massive ﬁbrosis (the “strawberry” in Figure 3D). In
these patients, there is no apparent curative ablation
approach, and multiple ablation sessions may even be
discouraged. Some of these patients may eventually
end up in atrial standstill, a loss of all electric and
mechanical activity (5). In parallel with technologicaldevelopments, the role of the right atrium in AF
ablation must also be re-addressed in some of these
AF patients (40).
CONCLUSIONS AND OUTLOOK:
THE PRESENT AND FUTURE
At present, for patients with persistent and/or long-
standing persistent AF, the success rate of stepwise
approaches that add anatomically deﬁned linear lines
and electrogram-based ablation after circumferential
PVI is disappointingly low, with a single-procedure
success rate of <25% at 5 years. We must develop
completely new strategies for substrate modiﬁcation,
with development toward patient-tailored indivi-
dualization of AF ablation. In contrast to purely
anatomically deﬁned (blind) lines, new substrate
modiﬁcation concepts target the individual location
and extent of the substrate.
One speciﬁc strategy in this direction is the precise
localization and ablation of rotors that maintain the
FIGURE 9 Focal Impulse and Rotor Mapping
Left Atrial Basket Left Atrial Rotor during AF
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(A) Contact multielectrode mapping in the left atrium, (B) organized left atrial rotor drives bi-atrial disorganization (scale bar 1 s), and (C) the
rotor is spatially reproducible within a region deﬁned by phase mapping. Courtesy of Sanjiv Narayan, MD. Abbreviations as in Figure 1.
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205arrhythmia using multielectrode mapping during AF.
The question that needs to be answered is if a speciﬁc
microarchitecture of the ﬁbrosis patterns determines
rotor location. Another useful strategy targets the
signiﬁcantly affected ﬁbrotic areas with EAVM
together with BIFAs, and uses a circular mapping
catheter for conﬁrmation. Finally, these 2 strategies
may be combined. In the future, individualized sub-
strate modiﬁcation may be added to circumferential
PVI even in some patients with paroxysmal AF
who have substantial regional LA ﬁbrosis, whereas
circumferential PVI may remain the sole ablation
target in other patients with persistent AF and who do
not have substantial LA ﬁbrosis.These new concepts will be supported in the future
by further reﬁnements in catheter technology using
point-by-point mapping and new catheter and/or
multielectrode arrays that allow simultaneous multi-
site contact mapping plus ablation. Obviously, we are
far from having solved the substrate modiﬁcation
target, but prospective randomized multicenter
studies investigating these new strategies will answer
these questions.
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